Business
GSK Abandons Camlipixant Cough Drug: Stock Falls as Much as 4.5%
British pharmaceutical group GSK announced on July 17, 2026, it is halting development of Camlipixant, an experimental drug for refractory chronic cough—a persistent cough that resists standard treatments. GSK stock fell as much as 4.5% following the announcement. The company had acquired the treatment for $2 billion, with revenue forecasts exceeding £2.5 billion annually. Late-stage clinical trials produced insufficient results in a second patient cohort, leading GSK to conclude the drug would not be transformative for patient care.